

IntraBio, co-founded by Department of Pharmacology academics Professors Fran Platt, Antony Galione and Grant Churchill, ran a successful international clinical trial for a new drug Aqneursa which showed significantly improved neurological outcomes over a 12 week period for a cohort of 60 patients, aged four years and over, with a confirmed diagnosis of NPC compared to a control group. Despite the recent proliferation of Drug Discovery Units in many Universities, it is nevertheless still rare for academics to take a new molecular entity from pre-clinical to phase III clinical trials culminating in regulatory approval and marketing for patients. The first prescriptions for Aqneursa have already been written.
NPC is a rare genetic disease that results in progressive neurological symptoms and organ dysfunction. It is caused by changes in either the NPC1 or NPC2 gene, affecting the transport of cholesterol and other lipids out of the lysosome. As a result, cells do not function as they should, ultimately causing organ damage. On average, individuals affected by this devastating disease only live for about 13 years. The new drug, Aqneursa, is only the third drug approved for the treatment of NPC, including miglustat, which was the first drug to be approved for lysosomal storage diseases that was developed by the Platt laboratory.
Read the full story on the Department of Pharmacology website.
more recommended stories
Action Video Games and Brain Health: Study Insights
Gaming and Brain Structure: What MRI.
Creatine May Boost Muscle Strength in Alzheimer’s Patients
Creatine Supplementation Shows Promise in Alzheimer’s.
New Drug STF-1623 Shows Promise in Treating Solid Tumors
STF-1623 Transforming ‘Cold’ Tumors into ‘Hot’.
Macrophage Microautophagy Supports Immune Readiness
A Breakthrough in Cellular Recycling Macrophages,.
The Role of α-Glucosidase in Type 2 Diabetes
α-Glucosidase Inhibition: Functional Food Compounds for.
Oral Bacteria Linked to Atherosclerosis
New Evidence Links Viridans Streptococci to.
CDI Test Shows Early Detection Potential in Alzheimer’s
Breakthrough Study Highlights Brain Blood Flow.
Prenatal Chlorpyrifos Exposure and Pediatric Brain Changes
A Growing Concern in Pediatric Neurodevelopment.
Valve Deterioration After TAVI: New Research Insights
The Growing Role of TAVI in.
FAST Walking Shows Promise in Post-Stroke Rehab
Stroke remains one of the leading.
Leave a Comment